ClinConnect ClinConnect Logo
Search / Trial NCT06672887

Enhancing Successful Return to Work of Employees With Cancer, by Supporting Employers (MiLES Intervention)

Launched by ACADEMISCH MEDISCH CENTRUM - UNIVERSITEIT VAN AMSTERDAM (AMC-UVA) · Nov 1, 2024

Trial Information

Current as of July 22, 2025

Recruiting

Keywords

Cancer Survivor Employee With Cancer Employer Return To Work Employment Manager Employee

ClinConnect Summary

This clinical trial, called the MiLES Intervention, is studying how to help employees with cancer successfully return to work. The trial aims to see if providing support to employers can make a difference in how employees with cancer transition back to their jobs compared to standard care. The study will involve 140 pairs of employees and their employers, who will be randomly assigned to either receive this special support or just the usual care. Researchers will follow these participants for 12 months to gather information on how well they are doing at work and in their personal lives.

To be eligible for this trial, employees must have been diagnosed with cancer within the last two years and be between 18 and 65 years old. They should currently be employed and either fully or partly off work due to their illness. Employers must be involved in supporting their employee through this process and should not have used the MiLES intervention before. Participants can expect to receive guidance and resources aimed at improving their work experience and overall quality of life during this challenging time.

Gender

ALL

Eligibility criteria

  • Inclusion criteria employees with cancer:
  • Diagnosed with cancer \<2 years earlier;
  • Being of working age (between 18-65 years, considering the Dutch retirement age of 67 years, and the study's follow-up period of one year);
  • In paid employment with an employer;
  • Having either an occupational physician at the involved occupational health service or a reintegration consultant at the involved reintegration service (e.g. working for an organization that is affiliated with one of the settings of this study);
  • Currently fully or partly sick-listed (\<2 years);
  • Able to understand and read Dutch for filling out questionnaires;
  • Having already informed their employer about their diagnosis of cancer, or intending to do so;
  • Not yet applied or planning to apply for an invalidity benefit under the WIA.
  • Inclusion criteria employers:
  • Supports and guides the participating employee with cancer during the period of sick leave and RTW. For example, as the direct supervisor or HR-manager;
  • Able to understand and read Dutch to be able to use the MiLES intervention and for filling out questionnaires;
  • Not yet familiar with the MiLES intervention.
  • Exclusion Criteria:
  • - Employees with cancer and their employers must participate as a dyad. If one party in the dyad is unable or unwilling to participate, the other party cannot participate either.

About Academisch Medisch Centrum Universiteit Van Amsterdam (Amc Uva)

The Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) is a leading academic medical center in the Netherlands, dedicated to advancing healthcare through innovative research, education, and patient care. Affiliated with the University of Amsterdam, AMC-UvA integrates clinical practice with cutting-edge biomedical research, fostering a multidisciplinary approach to medical challenges. The institution actively engages in clinical trials to enhance treatment options and improve patient outcomes, while promoting collaboration among healthcare professionals, researchers, and academic institutions globally. With a commitment to excellence and a focus on translational medicine, AMC-UvA plays a pivotal role in shaping the future of healthcare.

Locations

Arnhem, , Netherlands

Dordrecht, , Netherlands

Hengelo, , Netherlands

Utrecht, , Netherlands

Zeeland, , Netherlands

Patients applied

0 patients applied

Trial Officials

Sietske Tamminga, PhD

Principal Investigator

Amsterdam UMC, location AMC

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported